Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer

Clinical Advances in Hematology and Oncology

Volumn 12, Issue 11, 2014, Pages 737-748

  Tewari, Krishnansu S ^a,b   Monk, Bradley J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST JOSEPH HOSPITAL   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Angiogenesis; Bevacizumab; Carboplatin; Cisplatin; Paclitaxel; Recurrent cervical cancer; Topotecan

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; MITOLACTOL; NAVELBINE; PACLITAXEL; TOPOTECAN; VINBLASTINE; VINCRISTINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ALOPECIA; ANEMIA; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; DIARRHEA; HIGH RISK POPULATION; HUMAN; LEUKOPENIA; MTT ASSAY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; ANTAGONISTS AND INHIBITORS; FEMALE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; QUALITY OF LIFE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84911889728     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
2. Tewari KS, Monk BJ. Invasive cervical cancer. In: DiSaia PJ, Creasman WT, eds. Clinical Gynecologic Oncology. 8th ed. Philadelphia, PA: Elsevier Saunders, 2012.
3. Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007;25(20):2952-2965.
4. Tewari KS, Taylor JA, Liao SY, et al. Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model. Gynecol Oncol. 2000;77(1):137-148.
5. Tewari KS, Monk BJ. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep. 2005;7(6):419-434.
6. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985;3(8):1079-1085.
7. Thigpen JT, Blessing JA, DiSaia PJ, Fowler WC Jr, Hatch KD. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1989;32(2):198-202.
8. McGuire WP III, Arseneau J, Blessing JA, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1989;7(10):1462-1468.
9. Omura GA, Blessing JA, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1997;15(1):165-171.
10. Bloss JD, Blessing JA, Behrens BC, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2002;20(7):1832-1837.
11. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22(15):3113-3119.
12. Long HJ III, Bundy BN, Grendys EC Jr, et al; Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23(21):4626-4633.
13. Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1999;17(9):2676-2680.
14. Fiorica J, Holloway R, Ndubisi B, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol. 2002;85(1):89-94.
15. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(28):4649-4655.
16. Morris M, Blessing JA, Monk BJ, McGehee R, Moore DH. Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22(16):3340-3344.
17. Brewer CA, Blessing JA, Nagourney RA, McMeekin DS, Lele S, Zweizig SL. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100(2):385-388.
18. Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol. 2009;36(2):170-180.
19. Tewari KS. Patients with metastatic/recurrent cervical cancer should be treated with cisplatin plus paclitaxel. Clin Ovarian Cancer. 2011;4(2):90-93.
20. Tewari KS. A critical need for reappraisal of therapeutic options for women with metastatic and recurrent cervical carcinoma: commentary on Gynecologic Oncology Group protocol 204. Am J Hematol Oncol. 2010;9(1):31-34.
21. Tewari KS, Monk BJ. Beyond platinum for metastatic and recurrent carcinoma of the cervix. Onkologie. 2009;32(10):552-554.
22. Tewari KS, Monk BJ. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. Clin Adv Hematol Oncol. 2010;8(2):108-115.
23. Symonds RP, Davidson SE, Chan S, et al; Scottish Gynaecological Cancer Trials Group, Beatson West of Scotland Cancer Centre. SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer. Gynecol Oncol. 2011;123(1):105-109.
24. Bahadori HR, Green MR, Catapano CV. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother Pharmacol. 2001;48(3):188-196.
25. Tiersten AD, Selleck MJ, Hershman DL, et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol. 2004;92(2):635-638.
26. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(7):1069-1074.
27. Wright JD, Viviano D, Powell MA, et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol. 2006;103(2):489-493.
28. Arseneau J, Blessing JA, Stehman FB, McGehee R. A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study). Invest New Drugs. 1986;4(2):187-191.
29. Weiss GR, Green S, Hannigan EV, et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol. 1990;39(3):332-336.
30. McGuire WP III, Arseneau J, Blessing JA, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1989;7(10):1462-1468.
31. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748-1756.
32. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European- Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12(12):2654-2666.
33. Belani CP, Kearns CM, Zuhowski EG, et al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17(2):676-684.
34. Kitagawa R, Katsumata N, Yamanaka Y, et al. Phase II trial of paclitaxel and carboplatin in patients with recurrent or metastatic cervical carcinoma [ASCO abstract 5048]. J Clin Oncol. 2004;22(14 suppl).
35. Kitagawa R, Katsumata N, Ando M, et al. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. Gynecol Oncol. 2012;125(2):307-311.
36. Saito I, Kitagawa R, Fukuda H, et al. A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol. 2010;40(1):90-93.
37. Kitagawa R, Katsumata N, Shibata T, et al; Japan Clinical Oncology Group. A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505) [ASCO abstract 5006]. J Clin Oncol. 2012;30(15)(suppl).
38. Takekuma M, Hirashima Y, Ito K, et al. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study. Gynecol Oncol. 2012;126(3):341-345.
39. Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2010;116(1):44-49.
40. Tewari KS, Sill MW, Monk BJ, et al. Phase III randomized clinical trial of cisplatin plus paclitaxel vs the non-platinum chemotherapy doublet of topotecan plus paclitaxel in women with recurrent, persistent, or advanced cervical carcinoma: A Gynecologic Oncology Group study [SGO abstract 1]. Gynecol Oncol. 2013;130(1):e2.
41. Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer [press release]. National Cancer Institute. http://www. cancer.gov/newscenter/newsfromnci/2013/GOG240. Updated June 2, 2013. Accessed September 22, 2014.
42. Tewari KS, Sill MW, Long HJ III, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734-743.
43. Penson RT, Huang HQ, Tewari KS, et al. Patient reported outcomes in a randomized trial of bevacizumab in the treatment of advanced cervical cancer: A Gynecologic Oncology Group study [ECC LBA 42]. Eur J Cancer. 2013;49(suppl 3).
44. Tewari KS, Sill MW, Monk BJ, et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group study [SGO Women's Health abstract 143]. Gynecol Oncol. 2014;133(suppl 1):S59-S60.
45. Tewari KS, Sill MW, Moore DH, et al. High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from anti-angiogenesis therapy: a Gynecologic Oncology Group study [SGO Women's Health abstract 144]. Gynecol Oncol. 2014;133(suppl 1):S60.
46. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cervical Cancer. Version 1.2014. NCCN.org. http://www.nccn.org/professionals/ physician_gls/pdf/cervical.pdf.
47. Campbell D. Women with advanced cervical cancer in England to get Avastin. The Guardian. http://www.theguardian.com/society/2014/mar/06/women-advancedcervical- cancer-england-avastin. March 5, 2014. Accessed September 22, 2014.
48. FDA grants Genentech's Avastin priority review for certain types of cervical cancer [press release]. Genentech. http://www.gene.com/media/pressreleases/ 14569/2014-07-14/fda-grants-genentechs-avastin-priority-r. July 14, 2014. Accessed September 22, 2014.
49. FDA News Release. FDA approves Avastin to treat patients with aggressive and late-stage cervical cancer. US Food and Drug Administration. http://www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm410121.htm. August 14, 2014. Accessed September 22, 2014.
50. Gourley C, McCavigan A, Perren T, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome [ASCO abstract 5502]. J Clin Oncol. 2014;32(5)(suppl).
51. Eskander RN, Tewari KS. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol. 2014;26(4):314-321.
52. Eskander RN, Tewari KS. Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol. In press.
53. Eskander RN, Tewari KS. Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J Gynecol Oncol. 2014;25(3):249-259.
54. Krill LS, Adelson JW, Randall LM, Bristow RE. Clinical commentary: medical ethics and the ramifications of equipoise in clinical research. Is a confirmatory trial using a non-bevacizumab containing arm feasible in patients with recurrent cervical cancer? Gynecol Oncol. 2014;134(3):447-449.
55. Monk BJ, Tewari KS. Evidence-based therapy for recurrent cervical cancer. J Clin Oncol. 2014;32(25):2687-2690.
56. Eskander RN, Tewari KS. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma-mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol. 2014;132(2):496-505.
57. Tewari KS, Monk BJ. New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy [published online August 7, 2014]. Clin Cancer Res. doi:10.1158/1078-0432.CCR-14-1099.